In the current study, two pancreatic cancer cell lines (Panc-1 and MiaPaCa-2) were treated with pan-PAD inhibitor Cl-amidine alongside PAD2, PAD3, and PAD4 isozyme-specific inhibitors. Here, PADI4 is linked to pancreatic neoplasm.